# A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

> **NCT00823979** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 105 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** UK-453,061 Dose 1
- **DRUG:** UK-453,061 Dose 2
- **DRUG:** Etravirine

## Key facts

- **NCT ID:** NCT00823979
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03-25
- **Primary completion:** 2012-10-18
- **Final completion:** 2012-10-18
- **Target enrollment:** 105 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2018-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00823979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00823979, "A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00823979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*